214 related articles for article (PubMed ID: 25505080)
1. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines.
Coleman CB; Wohlford EM; Smith NA; King CA; Ritchie JA; Baresel PC; Kimura H; Rochford R
J Virol; 2015 Feb; 89(4):2301-12. PubMed ID: 25505080
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus Type 2 Infects T Cells in Healthy Kenyan Children.
Coleman CB; Daud II; Ogolla SO; Ritchie JA; Smith NA; Sumba PO; Dent AE; Rochford R
J Infect Dis; 2017 Sep; 216(6):670-677. PubMed ID: 28934430
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
6. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
7. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.
Lay JD; Tsao CJ; Chen JY; Kadin ME; Su IJ
J Clin Invest; 1997 Oct; 100(8):1969-79. PubMed ID: 9329960
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
10. Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome.
Chen G; Chen L; Qin X; Huang Z; Xie X; Li G; Xu B
Int J Clin Exp Pathol; 2014; 7(10):7110-3. PubMed ID: 25400806
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
12. T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals.
Tosato G; Magrath IT; Blaese RM
J Immunol; 1982 Feb; 128(2):575-9. PubMed ID: 6274959
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.
Neuhierl B; Feederle R; Hammerschmidt W; Delecluse HJ
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15036-41. PubMed ID: 12409611
[TBL] [Abstract][Full Text] [Related]
14. T-cell therapies for Epstein-Barr virus-associated lymphomas.
El-Bietar J; Bollard C
Pediatr Hematol Oncol; 2011 Nov; 28(8):627-39. PubMed ID: 22023461
[TBL] [Abstract][Full Text] [Related]
15. [Epstein-Barr virus penetration mechanism to T lymphoblastoid cell lines].
Uno M
Nihon Rinsho; 1997 Feb; 55(2):404-8. PubMed ID: 9046832
[TBL] [Abstract][Full Text] [Related]
16. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
Tse E; Kwong YL
Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
[TBL] [Abstract][Full Text] [Related]
17. Human peripheral blood and bone marrow Epstein-Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets.
Guerreiro M; Na IK; Letsch A; Haase D; Bauer S; Meisel C; Roemhild A; Reinke P; Volk HD; Scheibenbogen C
Eur J Immunol; 2010 Jun; 40(6):1566-76. PubMed ID: 20232341
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
[TBL] [Abstract][Full Text] [Related]
19. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
